EpiPen: latest news - GoINPHARMA
Sunday, 24 March 2019 - 22:46


Positive momentum for Teva: generic to Rituxan approved

Positive momentum for Teva, which has announced it has obtained the FDA approval for Truxima, a biosimilar to Rituxan (MabThera), a blockbuster by Genentech-Roche. Truxima has been developed by its South Korea-based partner Celltrion for the treatment of non-Hodgkin lymphoma….

FDA approves EpiPen’s generic developed by Teva, shares soar

FDA yesterday approved the generic to Mylan’s EpiPen, developed by Teva Pharmaceuticals. EpiPen is an epinephrine pre-filled syringe, to be used in case of anaphylactic shock. It is a blockbuster worth $1.5bn. Mylan’s price policy has resulted in price increases…

Mylan’s shareholders oppose $98m bonus to chairman Coury

Mylan’s shareholders voted against paying the group’s executives the 2016 bonus at their annual meeting in Amsterdam today. The decision is due to Mylan’s poor performance – indeed, its shares lost more than 30%, as the US government strongly pressured…

Mylan Q3 results affected by $465m settlement for EpiPen

US-based Mylan—incorporated in the Netherlands—announced its financial results for Q3 2016. These did not meet predictions, primarily due to the $465m paid on October 6th to US Authorities for the price policy adopted towards Medicaid for Epipen, Mylan’s life-saving treatment…